Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid generic competition, wrote Connor Hart for the Wall ...

Bayer’s Parkinson’s disease cell therapy is moving into late-stage testing, with the upcoming trial set to be the first registrational phase 3 study for an investigational allogeneic cell ...

Bayer BAYN-0.85%decrease; red down pointing triangle said the Federal Court of Australia closed the last pending case in the country over whether its Roundup weedkiller causes cancer, a win for ...

Krafton India has announced the start of registrations for the fourth edition of Battlegrounds Mobile India Series (BGIS) 2025. The tournament offers a ₹2 crore prize pool, with the LAN finals ...

Despite restructuring efforts, Bayer's financial outlook for 2025 remains weak, with anticipated declining earnings. Consensus estimates project $3-4 billion free cash flow for 2026-2027 ...